Enterprise支架治疗大脑中动脉症状性动脉粥样硬化性狭窄  

Enterprise stent for symptomatic atherosclorefic stenosis in middle cerebral arteries

作　　者：李梅[1] 朱晔宁[1] 廖瑜晖[1] 罗伟良[1] 刘武[1] 邓宇平[1] 何艳[1] 

机构地区：[1]惠州市中心人民医院神经内科,516001

出　　处：《中国实用医药》2013年第23期17-18,共2页China Practical Medicine

基　　金：惠州市科技计划项目(项目编号:2011y027)

摘　　要：目的评价Enterprise支架治疗大脑中动脉症状性动脉粥样硬化性狭窄的安全性及有效性。方法分析16例Enterprise支架治疗大脑中动脉症状性动脉粥样硬化性狭窄患者的近期疗效及支架内再狭窄发生情况。结果支架置入成功率为92.86%(15/16),术后6月NIHSS评分较术前明显改善,且差异有统计学意义(P<0.05)。支架内狭窄率为6.6%,仅1例出现支架内狭窄。结论 Enterprise支架治疗大脑中动脉症状性动脉粥样硬化性狭窄是安全的,支架内再狭窄发生率低。Objective To assess the safety and efficacy of the treatment for symptomatic athemselerotie middle cerebral artery stenosis with Enterprise stent. Methods 16 patients with symptomatic middle cerebral artery stetiose were treated using Enterprise stents, Efficacy of the treatment and restenosis were analyzed. Re- sults The technical success rate was 92. 86% （15/16）. 6 months after stenting, the scores of NIHSS were higher significantly （P 〈 0. 05）. In-stent restenosis rate was 6. 6%, only 1 in-stent restenosis. Conclusion The treatment for symptomatic athemselerotie middle cerebral artery stenosis with Enterprise stent is safe, in-stent restenosis rate is lower.

关 键 词：大脑中动脉 动脉粥样硬化 再狭窄 支架 

分 类 号：R743.3[医药卫生—神经病学与精神病学]